EP Patent

EP1032390A1 — Anaesthetic formulation

Assigned to Darwin Discovery Ltd · Expires 2000-09-06 · 26y expired

What this patent protects

A pharmaceutically acceptable aqueous solution which is isobaric or hyperbaric, and isotonic, with respect to cerebrospinal fluid (CSF), comprises a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide anaesthetic agent such as bupivacaine or levobupivacaine and a saccharide. I…

USPTO Abstract

A pharmaceutically acceptable aqueous solution which is isobaric or hyperbaric, and isotonic, with respect to cerebrospinal fluid (CSF), comprises a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide anaesthetic agent such as bupivacaine or levobupivacaine and a saccharide. If the amount of the anaesthetic agent is no more than 0.75 % w/v, a salt or another additional non-saccharide is present. Accordingly, the amount of the saccharide can be kept below that which would provide isotonicity in the absence of the additional non-saccharide.

Drugs covered by this patent

Patent Metadata

Patent number
EP1032390A1
Jurisdiction
EP
Classification
Expires
2000-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Darwin Discovery Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.